- Inovio Pharmaceuticals (NASDAQ:INO) is off 13% premarket on increased volume in response its announcement of the termination its INO-5150 prostate cancer co-development deal with Roche (OTCQX:RHHBY).
- The company plans to independently advance INO-5150 into Phase 1 in 1H 2015.
Inovio down on termination of Roche collaboration
Recommended For You
More Trending News
About INO Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
INO | - | - |
Inovio Pharmaceuticals, Inc. |